Gilead Sciences Inc (LTS:0QYQ)
$ 89.755 0.23 (0.26%) Market Cap: 112.32 Bil Enterprise Value: 132.90 Bil PE Ratio: 109.56 PB Ratio: 6.12 GF Score: 75/100

Gilead Sciences Inc at Leerink Partners Global Biopharma Conference Transcript

Mar 12, 2024 / 02:00PM GMT
Release Date Price: $75.07 (-0.15%)
Daina Michelle Graybosch
Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst

Okay. Good morning, everyone. My name is Daina Graybosch. I am analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite.

Cindy Perettie
Gilead Sciences, Inc. - EVP of Kite

Thank you. It's nice to be here.

Questions & Answers

Daina Michelle Graybosch
Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst

And so we're going to jump right in, because it's a busy year and busy week for CAR T. And we're going to talk all elements. So actually, let's start with BCMA. So Kite has licensed Arcellx's BCMA CAR T called Anito-Cel. And I wonder if you could talk about of all the potentially differentiating product attributes for Anito-Cel, which do you think will be most impactful in commercialization?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot